Addex Therapeutics LTD Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Timothy Mark Dyer, CEO of Addex Therapeutics Ltd, has filed an amendment to Schedule 13D detailing his beneficial ownership of 19,165,714 shares, representing 9.01% of the company, following a reduction in option strike prices.
NASDAQ
SCHEDULE: Addex Therapeutics CEO's Stake Update
Timothy Mark Dyer, CEO of Addex Therapeutics, has updated his beneficial ownership filing, now holding approximately 8.89% of the company's shares following recent share dilution.
NASDAQ
SCHEDULE 13D/A: Addex Therapeutics CEO Timothy Mark Dyer Boosts Stake to 12.94%
Timothy Mark Dyer, CEO of Addex Therapeutics Ltd., has increased his beneficial ownership in the company to 12.94% through a combination of share acquisitions, option exercises, and compensation.